Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM PRESERVATIVE FREE versus LIQUAEMIN LOCK FLUSH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM PRESERVATIVE FREE versus LIQUAEMIN LOCK FLUSH.
HEPARIN SODIUM PRESERVATIVE FREE vs LIQUAEMIN LOCK FLUSH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III (ATIII), causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and factor Xa, as well as factors IXa, XIa, and XIIa. This inhibits clot formation and propagation.
Heparin potentiates the activity of antithrombin III, thereby inactivating thrombin (factor IIa) and activated factor X (Xa), and preventing fibrin clot formation. It also inhibits factors IXa, XIa, and XIIa.
Initial bolus of 80 units/kg IV, followed by continuous infusion at 18 units/kg/hour IV; adjusted to maintain aPTT of 1.5-2.5 times control.
10-100 units/mL solution; flush intermittent intravenous catheters after each use with 1-5 mL; for central venous catheters, use 2-3 mL of 10 units/mL solution; for peripheral catheters, use 1-2 mL of 10 units/mL solution.
None Documented
None Documented
Terminal half-life is 0.5–2.5 hours (mean ~1.5 h) after IV administration; dose-dependent due to saturable clearance. At therapeutic doses, half-life averages 1–2 hours.
1-2 hours (dose-dependent; prolonged with higher doses, renal impairment, or in elderly).
Primarily renal; small amounts in urine as unchanged drug and metabolites. Biliary/fecal elimination is negligible (<5%).
Renal (predominantly via reticuloendothelial system and liver metabolism; unchanged drug excreted in urine).
Category A/B
Category C
Anticoagulant
Anticoagulant